Stay updated on BGB324 with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the BGB324 with Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoChange Detected- Revision metadata updated: added Revision: v3.4.3. The Melanoma label and the MedlinePlus Genetics topic were removed, and Revision: v3.4.2 was deleted.SummaryDifference0.2%

- Check13 days agoChange DetectedAdded Melanoma as a related topic and MedlinePlus Genetics as a related topic on the page.SummaryDifference0.2%

- Check20 days agoChange DetectedAdded related topics Melanoma and MedlinePlus Genetics to the study page.SummaryDifference0.2%

- Check27 days agoChange DetectedMelanoma and MedlinePlus Genetics were removed from the related topics section on the page.SummaryDifference0.2%

- Check34 days agoChange DetectedThe page updated to Revision: v3.4.2 and removed the prior notices including the lapsed funding notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedSite-wide notice about government funding and NIH operating status was added, and the page version was updated from 3.4.0 to 3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to BGB324 with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.